Capillary Leakage Syndrome Following the Administration of AstraZeneca Vaccine; Case report
Vaccination is a highly effective medical intervention in the COVID-19 pandemic. Systemic Capillary Leakage Syndrome (SCLS) is a severe and rare condition that can occur following COVID-19 vaccination, leading to recurrent shock episodes in patients. This report highlights a case where a patient experienced leakage syndrome after receiving the AstraZeneca vaccine. The 31-year-old female patient experienced shortness of breath, blood pressure drops, edema, and limb coldness 48 hours after receiving the COVID-19 vaccine. The clinical assessments identified low blood pressure, rapid heart rate, and reduced breath sounds at the bases of the lungs. Bilateral pleural effusion was observed in a chest CT scan, and pericardial effusion of moderate severity was seen in echocardiography. Laboratory tests showed leukocytosis, hyponatremia, hypoalbuminemia, hypocalcemia, and transudative pleural fluid. The remaining observations fell within standard parameters. Measures such as fluid restriction, correction of electrolyte imbalances, prescription of corticosteroids, and antibiotic therapy were applied. These interventions resulted in an improvement in the patient's overall condition, leading to the resolution of her symptoms. Since the symptoms of leakage syndrome are non-specific, and its diagnosis is based on excluding other causes, and considering that no paraneoplastic evidence was found in the studied patient, the diagnosis of leakage syndrome was attributed to the individual. For individuals exhibiting hypovolemic shock and edema linked to pleural effusion or ascites, and upon excluding conditions such as nephrotic syndrome, hypercoagulability syndromes, sepsis, and connective tissue vascular diseases, attention should be directed towards the possibility of leakage syndrome. Supportive care is the mainstay of treatment in these patients, and fluid restriction is a key component of management. Awareness of the symptoms and signs of this syndrome, as well as factors that may trigger its recurrence, is essential for physicians to make appropriate decisions for timely diagnosis and treatment in similar cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal of Mazandaran University of Medical Sciences - 33(2024), 229, Seite 87-92 |
| Sprache: |
Englisch ; Persisch |
|---|
| Beteiligte Personen: |
Sepideh Safanavaiee [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
Astrazeneca vaccine |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ100807097 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ100807097 | ||
| 003 | DE-627 | ||
| 005 | 20240414125857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240414s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ100807097 | ||
| 035 | |a (DE-599)DOAJd3a81f7653bf42e6885bdbb1e005f9ab | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a per | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Sepideh Safanavaiee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Capillary Leakage Syndrome Following the Administration of AstraZeneca Vaccine; Case report |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Vaccination is a highly effective medical intervention in the COVID-19 pandemic. Systemic Capillary Leakage Syndrome (SCLS) is a severe and rare condition that can occur following COVID-19 vaccination, leading to recurrent shock episodes in patients. This report highlights a case where a patient experienced leakage syndrome after receiving the AstraZeneca vaccine. The 31-year-old female patient experienced shortness of breath, blood pressure drops, edema, and limb coldness 48 hours after receiving the COVID-19 vaccine. The clinical assessments identified low blood pressure, rapid heart rate, and reduced breath sounds at the bases of the lungs. Bilateral pleural effusion was observed in a chest CT scan, and pericardial effusion of moderate severity was seen in echocardiography. Laboratory tests showed leukocytosis, hyponatremia, hypoalbuminemia, hypocalcemia, and transudative pleural fluid. The remaining observations fell within standard parameters. Measures such as fluid restriction, correction of electrolyte imbalances, prescription of corticosteroids, and antibiotic therapy were applied. These interventions resulted in an improvement in the patient's overall condition, leading to the resolution of her symptoms. Since the symptoms of leakage syndrome are non-specific, and its diagnosis is based on excluding other causes, and considering that no paraneoplastic evidence was found in the studied patient, the diagnosis of leakage syndrome was attributed to the individual. For individuals exhibiting hypovolemic shock and edema linked to pleural effusion or ascites, and upon excluding conditions such as nephrotic syndrome, hypercoagulability syndromes, sepsis, and connective tissue vascular diseases, attention should be directed towards the possibility of leakage syndrome. Supportive care is the mainstay of treatment in these patients, and fluid restriction is a key component of management. Awareness of the symptoms and signs of this syndrome, as well as factors that may trigger its recurrence, is essential for physicians to make appropriate decisions for timely diagnosis and treatment in similar cases | ||
| 650 | 4 | |a systemic capillary leak syndrome | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a astrazeneca vaccine | |
| 650 | 4 | |a polyserositis | |
| 650 | 4 | |a pleural effusion | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Parastoo Karimi Aliabadi |e verfasserin |4 aut | |
| 700 | 0 | |a Narges Mirzaei Ilali |e verfasserin |4 aut | |
| 700 | 0 | |a Mehrnoush Sohrab |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Mazandaran University of Medical Sciences |d Mazandaran University of Medical Sciences, 2018 |g 33(2024), 229, Seite 87-92 |w (DE-627)DOAJ000073067 |x 17359279 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2024 |g number:229 |g pages:87-92 |
| 856 | 4 | 0 | |u https://doaj.org/article/d3a81f7653bf42e6885bdbb1e005f9ab |z kostenfrei |
| 856 | 4 | 0 | |u http://jmums.mazums.ac.ir/article-1-20197-en.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1735-9260 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1735-9279 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2024 |e 229 |h 87-92 | ||